IJNRD Research Journal

WhatsApp
Click Here

WhatsApp editor@ijnrd.org
IJNRD
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)

Call For Paper

For Authors

Forms / Download

Published Issue Details

Editorial Board

Other IMP Links

Facts & Figure

Impact Factor : 8.76

Issue per Year : 12

Volume Published : 9

Issue Published : 94

Article Submitted :

Article Published :

Total Authors :

Total Reviewer :

Total Countries :

Indexing Partner

Join RMS/Earn 300

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Published Paper Details
Paper Title: Immuno-oncology agents for cancer therapy
Authors Name: Shubham .S .Sanap , SUMEDH S. SHIVGAN , Yogita M.Vispute , Ashwini R.Bharati , puja G.Vyawhare
Download E-Certificate: Download
Author Reg. ID:
IJNRD_186177
Published Paper Id: IJNRD2301198
Published In: Volume 8 Issue 1, January-2023
DOI:
Abstract: Until recently, cancer therapy comprised of four main types of treatment: surgery, radiotherapy, chemotherapy, and targeted therapy. Over the past decade, immuno-oncology (IO) has emerged as a novel and important approach to cancer treatment through the stimulation of the body’s own immune system to kill cancer cells. This newly recognised method of treating cancer is rapidly developing, with many accelerated approvals by the US Food and Drug Administration and European Medicines Agency in 2019.[8] Several therapeutic classes have emerged within IO and are the focus of this review article. In particular, the immune checkpoint inhibitors have had remarkable success across multiple malignancies and are the most well- established therapeutic class of IO agents to date. Biomarker testing for the programmed death-ligand 1 (PD-L1) checkpoint target has been developed and is now obligatory before treatment with pembrolizumab (Keytruda, Merck) when used for non-small-cell lung carcinoma, gastric cancer, head and neck squamous cell carcinoma and cervical cancer, as well as before treatment with atezolizumab (Tecentriq, Roche) when used for urothelial carcinoma. However, ambiguity remains as to the relevance of PD-L1 expression for checkpoint inhibition therapy for other tumour types. More recently, combining IO agents with conventional therapies has been evaluated with some significant improvements in patient outcomes.
Keywords: Immuno-oncology agents for cancer therapy
Cite Article: "Immuno-oncology agents for cancer therapy", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 1, page no.b795-b809, January-2023, Available :http://www.ijnrd.org/papers/IJNRD2301198.pdf
Downloads: 000118745
ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publication Details: Published Paper ID:IJNRD2301198
Registration ID: 186177
Published In: Volume 8 Issue 1, January-2023
DOI (Digital Object Identifier):
Page No: b795-b809
Country: -, -, -
Research Area: Engineering
Publisher : IJ Publication
Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2301198
Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2301198
Share Article:
Share

Click Here to Download This Article

Article Preview
Click Here to Download This Article

Major Indexing from www.ijnrd.org
Semantic Scholar Microsaoft Academic ORCID Zenodo
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX PUBLON
DRJI SSRN Scribd DocStoc

ISSN Details

ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016

DOI (A digital object identifier)


Providing A digital object identifier by DOI
How to Get DOI? DOI

Conference

Open Access License Policy

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Creative Commons License This material is Open Knowledge This material is Open Data This material is Open Content

Important Details

Social Media

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Join RMS/Earn 300

IJNRD